The phase III JAVELIN Gastric 100 trial (Moehler et al. 2019) showed no significant OS benefits with first-line avelumab maintenance therapy compared with continued chemotherapy in patients with HER2-negative GC. This evidence concerns the gene ERBB2 and gastric cancer.